Navigation Links
LLS's Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
Date:9/20/2012

WHITE PLAINS, N.Y., Sept. 20, 2012 /PRNewswire/ -- Thanks to support funding from The Leukemia & Lymphoma Society (LLS), Onconova Therapeutics, Inc. has been advancing rigosertib, the lead compound under development for treating patients with high-risk myelodysplastic syndrome (MDS). 

In an announcement made this week, European commercial rights for rigosertib have been licensed to Baxter International providing significant resources to advance the program toward U.S. and European regulatory review and ultimately to MDS patients.  Rigosertib is designed to inhibit critical pathways to the growth and survival of cancer cells. 

"Advancing new therapies in areas of unmet medical need such as MDS is the bow of the ship for LLS," said LLS President and CEO John Walter. "The Baxter/Onconova agreement highlights a successful outcome for the LLS Therapy Acceleration Program (TAP)."

LLS and Onconova first announced their collaboration in June 2010. LLS has committed to providing up to $12.5 million in funding to support an ongoing multicenter, randomized, clinical trial of rigosertib versus best supportive care in adult patients with MDS who have relapsed or become resistant to azacitidine or decitabine. Onconova has announced that, to date, trial enrollment has successfully surpassed the half-way point and there are now 80 trial sites activated around the globe.  Onconova is continuing to accrue patients for the clinical trial.

This partnership marks the first phase 3, approval-track clinical trial that LLS is supporting through TAP, a bold initiative designed to bring promising therapies to patients suffering from blood cancers more quickly.  LLS is taking an active role in accelerating development of novel therapies for patients and has committed substantial, multi-year funding to support this collaboration with Onconova as part of TAP.  LLS continues to partner directly with other biotechnology companies through TAP to accelerate the advancement of potential breakthrough therapies towards FDA approval.

LLS proudly recognizes the significant support provided by Edward P. Evans Foundation and Harry T. Mangurian, Jr. Foundation for this project.

About MDS
Myelodysplastic syndromes (MDS) are a group of diseases of the blood and marrow, with varying degrees of severity and life expectancy. In the general population, MDS occurs in 5 per 100,000 people. However, among individuals older than age 70, the incidence increases to between 22 and 45 per 100,000, increasing even further with age.  Most often, people diagnosed with MDS first seek medical attention because they are experiencing fatigue and shortness of breath. MDS may be a primary (de novo) diagnosis or secondary to cancer treatment with chemotherapy and/or radiation therapy. MDS has been known as "smoldering leukemia," or "pre-leukemia," implying that MDS is only serious and problematic if it evolves into AML; this is not the case.

While there has been recent progress toward improving management of MDS, therapeutic options are limited for patients who have drug-resistant or refractory disease. The only potential cure is stem cell transplantation from a donor. However, patients who have MDS may not be candidates for this option due to their advanced age and underlying bone marrow deficit. Novel therapeutic strategies are needed and to date, rigosertib has shown clinical promise in multiple trials.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

Contact: LLS: Andrea Greif
(914) 821-8958 andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
2. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
3. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
5. New gene therapy strategy boosts levels of deficient protein in Friedreichs ataxia
6. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
7. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
8. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
9. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
10. Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
11. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 08, 2016 , ... ... multilingual testing services, announced today the launch of its revamped and improved website. ... scalable language service solutions, the redesigned website will better communicate how the company ...
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry ... Access publishing is one of the popular publication models that has received wider ... and 3000+ International Conferences across the globe, OMICS International is ...
(Date:2/9/2016)... and LONDON , February 9, 2016 ... bio tech replace paper and protect IP ... electronic laboratory notebook (ELN) will be rolled out in ... research and development (R&D) and protect valuable IP. Users will ... follow a specific researcher or experiment as part of the ...
(Date:2/8/2016)... 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... finalists for clean technology companies in the TSX Venture 50 ... companies listed on the TSX Venture Exchange, in each of ... clean technology & life sciences, diversified industries and technology ... to return on investment, market cap growth, trading volume and ...
Breaking Biology Technology:
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... India , February 3, 2016 ... the new market research report "Automated Fingerprint Identification System ... Search, Latent Search), Application (Banking & Finance, Government, Healthcare, ... published by MarketsandMarkets, the market is expected to be ... CAGR of 21.0% between 2015 and 2020. The transformation ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
Breaking Biology News(10 mins):